IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center - IRCCS -, Rozzano, Italy.
Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Science, Chinese University of Hong Kong, Hong Kong, China.
Nat Rev Dis Primers. 2020 Apr 2;6(1):22. doi: 10.1038/s41572-020-0156-2.
Crohn's disease is an inflammatory bowel disease that is characterized by chronic inflammation of any part of the gastrointestinal tract, has a progressive and destructive course and is increasing in incidence worldwide. Several factors have been implicated in the cause of Crohn's disease, including a dysregulated immune system, an altered microbiota, genetic susceptibility and environmental factors, but the cause of the disease remains unknown. The onset of the disease at a young age in most cases necessitates prompt but long-term treatment to prevent disease flares and disease progression with intestinal complications. Thus, earlier, more aggressive treatment with biologic therapies or novel small molecules could profoundly change the natural history of the disease and decrease complications and the need for hospitalization and surgery. Although less invasive biomarkers are in development, diagnosis still relies on endoscopy and histological assessment of biopsy specimens. Crohn's disease is a complex disease, and treatment should be personalized to address the underlying pathogenetic mechanism. In the future, disease management might rely on severity scores that incorporate prognostic factors, bowel damage assessment and non-invasive close monitoring of disease activity to reduce the severity of complications.
克罗恩病是一种炎症性肠病,其特征为胃肠道任何部位的慢性炎症,具有进行性和破坏性病程,且全球发病率呈上升趋势。多种因素与克罗恩病的病因有关,包括免疫系统失调、微生物群改变、遗传易感性和环境因素,但病因仍未知。大多数情况下,该病在年轻时发病,需要及时但长期的治疗,以预防疾病发作和疾病进展并出现肠道并发症。因此,更早、更积极地使用生物疗法或新型小分子药物治疗,可能会显著改变疾病的自然病程,并减少并发症以及住院和手术的需求。虽然正在开发侵入性更小的生物标志物,但诊断仍依赖于内镜和活检标本的组织学评估。克罗恩病是一种复杂的疾病,治疗应针对潜在的发病机制进行个体化。未来,疾病管理可能依赖于严重程度评分,该评分纳入预后因素、肠道损伤评估以及疾病活动的非侵入性密切监测,以降低并发症的严重程度。